US Stock MarketDetailed Quotes

TAK Takeda Pharmaceutical

Watchlist
  • 14.375
  • +0.035+0.24%
Trading Feb 27 09:58 ET
45.57BMarket Cap32.74P/E (TTM)

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Company Profile

SymbolTAK
Company NameTakeda Pharmaceutical
Listing DateDec 24, 2018
Founded1781
CEOMr. Christophe Weber
MarketNYSE
Employees49281
Securities TypeDR
ADS Ratio2.0 : 1.0
Fiscal Year Ends03-31
Address4-1-1 Dosho-machi,Chuo-Ku
CityOsaka
ProvinceOsaka
CountryJapan
Zip Code540-8645
Phone81-6-6204-2111

Company Executives

  • Name
  • Position
  • Salary
  • Akiko Amakawa
  • Corporate Strategy Officer and Chief Executive Officer Chief of Staff
  • --
  • Christophe Weber
  • Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.a., Inc.
  • 1.70B
  • Gabriele Ricci
  • Chief Data and Technology Officer
  • --
  • Mwana Lugogo
  • Chief Ethics and Compliance Officer
  • --
  • Milano Furuta
  • Director and Chief Financial Officer
  • --
  • Takako Ohyabu
  • Chief Global Corporate Affairs and Sustainability Officer
  • --
  • Lauren Duprey
  • Chief Human Resources Officer
  • --
  • Marcello Agosti
  • Global Business Development Officer
  • --
  • Elaine Shannon
  • Global Quality Officer
  • --
  • Dr. Thomas Wozniewski, PhD
  • Global Manufacturing and Supply Officer
  • --
  • Asuka Miyabashira
  • President, Japan Pharma Business Unit
  • --
  • Teresa Marie Bitetti
  • President, Global Oncology Business Unit
  • --
  • Giles Platford
  • President, Plasma-Derived Therapies Business Unit
  • --
  • Masami Iijima
  • Chairman of the Board
  • 43.00M
  • Andrew S. Plump, M.D.
  • Director and President, Research and Development
  • 12.00M
  • Ramona Sequeira
  • President, Global Portfolio Division
  • --
  • Julie Kim
  • President, U.S. Business Unit and U.S. Country Head
  • --
  • Dr. Steven Gillis, Pd.D
  • Independent Director
  • 44.00M
  • Koji Hatsukawa
  • Independent Director
  • 43.00M
  • Michel Orsinger
  • Independent Director
  • 46.00M
  • Jean-Luc Butel
  • Independent Director
  • 38.00M
  • Ian T. Clark
  • Independent Director
  • 44.00M
  • Dr. John M. Maraganore,PhD
  • Independent Director
  • 39.00M
  • Kimberly A. Reed
  • Independent Director
  • 41.00M
  • Emiko Higashi
  • Independent Director
  • 49.00M
  • Yoshiaki Fujimori
  • Independent Director
  • 40.00M
  • Miki Tsusaka
  • Independent Director
  • 32.00M
  • Yoshihiro Nakagawa
  • Global General Counsel
  • --

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Unlock Now
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More